Passive administration of monoclonal antibodies to Anthrolysin O prolong survival in mice lethally infected with Bacillus anthracis

Background Bacillus anthracis has two major virulence factors: a tripartite toxin that produces lethal and edema toxins and a polyglutamic acid capsule. A recent report suggested that a toxin belonging to the cholesterol dependant cytolysin (CDC) family, anthrolysin O (ALO) was a new virulence factor for B. anthracis but subsequent studies have questioned its relevance in pathogenesis. In this study, we examined the immunogenicity of recombinant anthrolysin O (rALO) in mice. Results BALB/c mice immunized with rALO and boosted after two weeks, produce sera with strong Ab responses with a predominance of IgG1 and IgG2a. Five hybridomas to rALO were recovered representing the IgM, IgG1, and IgG2b isotypes. Passive administration of 3 of the five monoclonal antibodies (mAbs) to rALO prior to infection with lethal intravenous (i.v.) B. anthracis Sterne strain infection in mice was associated with enhanced average survival and a greater likelihood of surviving infection. A combination of two mAbs to ALO was more effective than either mAb separately. One mAb (64F8) slowed the toxicity of rALO for J774.16 macrophage-like cells. Conclusion Our results suggest that ALO contributes to the virulence of B. anthracis Sterne strain in this infection model and that Ab response to ALO may contribute to protection in certain circumstances..

Medienart:

E-Artikel

Erscheinungsjahr:

2008

Erschienen:

2008

Enthalten in:

Zur Gesamtaufnahme - volume:8

Enthalten in:

BMC microbiology - 8(2008), 1 vom: 23. Sept.

Sprache:

Englisch

Beteiligte Personen:

Nakouzi, Antonio [VerfasserIn]
Rivera, Johanna [VerfasserIn]
Rest, Richard F [VerfasserIn]
Casadevall, Arturo [VerfasserIn]

Links:

Volltext [lizenzpflichtig]

Themen:

Bacillus Anthracis
Edema Toxin
Lethal Toxin
Passive Administration
Virulence Phenotype

Anmerkungen:

© Nakouzi et al; licensee BioMed Central Ltd. 2008. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (

doi:

10.1186/1471-2180-8-159

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

SPR027179818